General
Preferred name
fluvoxamine
Synonyms
FLUVOXAMINE MALEATE ()
DU-23000 (maleate) ()
MK-264 ()
DU-23000 (maleate)MK-264 ()
Fluvoxamine maleate ()
DU-23000 ()
Luvox ()
Fluvoxamine (maleate) ()
MK 264 {maleate} ()
Fluvoxamine (DU-23000) maleate ()
MK-264,DU-23000 maleate ()
Fluvoxamine hydrogenmaleate ()
Faverin 50 ()
Floxyfral ()
NSC-759602 ()
Faverin ()
DU23000 ()
Faverin 100 ()
Fevarin ()
Luvox cr ()
Fluvoxamina ()
N06AB08 ()
Fluvoxamine-d4 (maleate) ()
P&D ID
PD013179
CAS
54739-18-3
54739-20-7
61718-82-9
Tags
available
drug
Approved by
FDA
First approval
1994
Drug indication
Anxiety disorder
Depression
Antiobsessional Agent
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCPRITION
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
TOXICITY
Fluvoxamine is a member of antidepressants that possess an increased risk compared to placebo of suicidal thinking and behaviour (suicidality) in children, adolescents, and young adults (ages including and and below 24) in short-term studies of major depressive disorder and other psychiatric disorders [FDA Label].; ; Fluvoxamine maleate tablets are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) [FDA Label].; ; Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome [FDA Label].
DESCRIPTION
Fluvoxamine is an antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) drug group.
Marketed formulations may contain fluvoxamine maleate (PubChem CID 9560989).
SARS-CoV-2 and COVID-19: Evidence that is emerging from randomised, placebo-controlled clinical trials suggests that fluvoxamine may offer potential as a therapuetic for non-hospitalised COVID-19 patients. Multiple fluvoxamine mechanisms of action may be at play , and much remains to clarified about the patients who would benefit most, efficacy in infections with different SARS-CoV-2 variants, and whether fluvoxamine's effect occurs in addition to the benefit demonstrated by other therapies. (GtoPdb)
Marketed formulations may contain fluvoxamine maleate (PubChem CID 9560989).
SARS-CoV-2 and COVID-19: Evidence that is emerging from randomised, placebo-controlled clinical trials suggests that fluvoxamine may offer potential as a therapuetic for non-hospitalised COVID-19 patients. Multiple fluvoxamine mechanisms of action may be at play , and much remains to clarified about the patients who would benefit most, efficacy in infections with different SARS-CoV-2 variants, and whether fluvoxamine's effect occurs in addition to the benefit demonstrated by other therapies. (GtoPdb)
DESCRIPTION
I1 selective ligand
(Tocris Bioactive Compound Library)
DESCRIPTION
Selective serotonin reuptake inhibitor
(LOPAC library)
DESCRIPTION
5-HT re-uptake inhibitor
(Tocriscreen Total)
DESCRIPTION
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. It is effective in inhibiting 5-ht uptake by blood platelets and brain synaptosomes. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
36
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Total
VGSC-DB
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
61
Molecular Weight
318.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
1
Aromatic Ring Count
1
cLogP
3.2
TPSA
56.84
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Reuptake
MOA
serotonin transporter inhibitor
Inhibitor
5-HT Reuptake Inhibitors
selective serotonin reuptake inhibitor (SSRI)
Target
Serotonin Transporter
5-HT
SLC6A4
SSRI
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Primary Target
5-HT Transporters
Member status
member
Indication
obsessive compulsive disorder (OCD)
Therapeutic Class
Antidepressants
VGSC Target
Nav1.5
Source data
